Editas Medicine (0IFK) Share Forecast & Price Target
0IFK Analyst Ratings
Moderate Buy
6Buy1Hold1Sell
Based on 8 analysts giving stock ratings to Editas Medicine in the past 3 months
0IFK Stock 12 Month Forecast
Average Price Target
$5.67â–˛(117.11% Upside)Based on 8 Wall Street analysts offering 12 month price targets for Editas Medicine in the last 3 months. The average price target is $5.67 with a high forecast of $8.00 and a low forecast of $4.00. The average price target represents a 117.11% change from the last price of $2.61.
Past 12 Months12 Month ForecastDec2025Sep2026
High$8.00
Average$5.67
Low$4.00
Highest Price TargetHighest$8.00Average Price Target$5.67Lowest Price TargetLowest$4.00
Detailed List of Analyst Forecasts​
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Yanan Zhu | Wells Fargo | $6 | buy | 129.89%Upside | Upgraded | 10/08/26 | ||
| Debjit Chattopadhyay | Guggenheim | $5 | buy | 91.57%Upside | Upgraded | 09/23/26 | ||
| Rick Bienkowski | Ladenburg Thalmann & Co. | $6 | buy | 129.89%Upside | Initiated | 08/18/26 | ||
| Alec Stranahan | Bank of America Securities | ― | sell | ― | Reiterated | 08/07/26 | ||
| Mitchell Kapoor | H.C. Wainwright | $3→$5 | buy | 91.57%Upside | Reiterated | 08/06/26 | ||
| Boris Peaker | JonesTrading | $8 | buy | 206.51%Upside | Reiterated | 08/05/26 | ||
| Phil Nadeau | TD Cowen | ― | buy | ― | Reiterated | 08/05/26 | ||
| Luca Issi | RBC Capital | $4 | hold | 53.26%Upside | Reiterated | 08/05/26 | ||
| Jonathan Miller | Evercore ISI | $15 | buy | 474.71%Upside | Reiterated | 05/27/26 | ||
| Geulah Livshits | Chardan Capital | $4 | buy | 53.26%Upside | Reiterated | 05/05/26 | ||
| Joon Lee | UBS | ― | hold | ― | Reiterated | 03/17/26 | ||
| Brian Cheng | J.P. Morgan | ― | sell | ― | Reiterated | 03/13/26 | ||
| William Maughan | Clear Street | $4.60 | buy | 76.25%Upside | Reiterated | 03/10/26 | ||
| Gena Wang | Barclays | $3 | hold | 14.94%Upside | Reiterated | 11/11/25 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Yanan Zhu | 10/08/26 | $6 | buy | 129.89%Upside | Upgraded | Wells Fargo | ||
| Debjit Chattopadhyay | 09/23/26 | $5 | buy | 91.57%Upside | Upgraded | Guggenheim | ||
| Rick Bienkowski | 08/18/26 | $6 | buy | 129.89%Upside | Initiated | Ladenburg Thalmann & Co. | ||
| Alec Stranahan | 08/07/26 | ― | sell | ― | Reiterated | Bank of America Securities | ||
| Mitchell Kapoor | 08/06/26 | $3→$5 | buy | 91.57%Upside | Reiterated | H.C. Wainwright | ||
| Boris Peaker | 08/05/26 | $8 | buy | 206.51%Upside | Reiterated | JonesTrading | ||
| Phil Nadeau | 08/05/26 | ― | buy | ― | Reiterated | TD Cowen | ||
| Luca Issi | 08/05/26 | $4 | hold | 53.26%Upside | Reiterated | RBC Capital | ||
| Jonathan Miller | 05/27/26 | $15 | buy | 474.71%Upside | Reiterated | Evercore ISI | ||
| Geulah Livshits | 05/05/26 | $4 | buy | 53.26%Upside | Reiterated | Chardan Capital | ||
| Joon Lee | 03/17/26 | ― | hold | ― | Reiterated | UBS | ||
| Brian Cheng | 03/13/26 | ― | sell | ― | Reiterated | J.P. Morgan | ||
| William Maughan | 03/10/26 | $4.60 | buy | 76.25%Upside | Reiterated | Clear Street | ||
| Gena Wang | 11/11/25 | $3 | hold | 14.94%Upside | Reiterated | Barclays |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Editas Medicine
3 Months
Success Rate4/8 ratings generated profit
50%
Average Return
+11.22%
Copying Mitchell Kapoor's trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +11.22% per trade.
1 Year
Success Rate8/15 ratings generated profit
53%
Average Return
+10.88%
Copying Phil Nadeau's trades and holding each position for 1 Year would result in 53.33% of your transactions generating a profit, with an average return of +10.88% per trade.
2 Years
Success Rate7/15 ratings generated profit
47%
Average Return
+3.90%
Copying Phil Nadeau's trades and holding each position for 2 Years would result in 46.67% of your transactions generating a profit, with an average return of +3.90% per trade.
0IFK Analyst Recommendation Trends
| Rating | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 |
|---|---|---|---|---|---|
| Strong Buy | 6 | 4 | 3 | 4 | 5 |
| Buy | 2 | 2 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 |
| Sell | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 10 | 8 | 6 | 7 | 8 |
In the current month, 0IFK has received 6 Buy Ratings, 1 Hold Ratings, and 1 Sell Ratings. 0IFK average Analyst price target in the past 3 months is 5.67.
0IFK Financial Forecast
High$-0.13
Consensus$-0.19
Low$-0.25
0IFK Earnings Forecast
Next quarter’s earnings estimate for 0IFK is -$0.19 with a range of -$0.25 to -$0.13. The previous quarter’s EPS was -$0.15. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
High$12M
Consensus$4.54M
Low$500K
0IFK Sales Forecast
Next quarter’s sales forecast for 0IFK is $4.54M with a range of $500.00K to $12.01M. The previous quarter’s sales results were $11.89M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
0IFK Stock Forecast FAQ
What is GB:0IFK’s average 12-month price target, according to analysts?
Based on analyst ratings, Editas Medicine’s 12-month average price target is $5.67.
What is GB:0IFK’s upside potential, based on the analysts’ average price target?
Editas Medicine has 117.11% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Editas Medicine a Buy, Sell or Hold?
Editas Medicine has a consensus rating of Moderate Buy, which is based on 6 buy ratings, 1 hold ratings and 1 sell ratings.
What is Editas Medicine’s share price target?
The average share price target for Editas Medicine is $5.67. This is based on 8 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is $8.00, and the lowest forecast is $4.00. The average share price target represents a 117.11% increase from the current price of $2.61.
What do analysts say about Editas Medicine?
Editas Medicine’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 8 Wall Street analysts.
How can I buy shares of Editas Medicine?
To buy shares of GB:0IFK, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
